Oncogenic transformation by adenovirus E1A and E1B-55K requires E1B-55K inhibition of p53 activity to prevent E1A-induced apoptosis. During viral infection, E1B-55K and E4orf6 substitute for the substratebinding subunits of the host cell cullin 5 class of ubiquitin ligases, resulting in p53 polyubiquitinylation and proteasomal degradation. Here we show that E1B-55K alone also functions as an E3 SUMO1-p53 ligase. Fluorescence microscopy studies showed that E1B-55K alone, in the absence of other viral proteins, causes p53 to colocalize with E1B-55K in promyelocytic leukemia (PML) nuclear bodies, nuclear domains with a high concentration of sumoylated proteins. Photobleaching experiments with live cells revealed that E1B-55K tethering of p53 in PML nuclear bodies decreases the in vivo nuclear mobility of p53 nearly 2 orders of magnitude. E1B-55K-induced p53 sumoylation contributes to maximal inhibition of p53 function since mutation of the major p53 sumoylation site decreases E1B-55K-induced p53 sumoylation, tethering in PML nuclear bodies, and E1B-55K inhibition of p53 activity. Mutation of the E1B-55K sumoylation site greatly inhibits E1B-55K association with PML nuclear bodies and the p53 nuclear export to cytoplasmic aggresomes observed in E1A-E1B-transformed cells. Purified E1B-55K and p53 form high-molecular-weight complexes potentially through the formation of a network of E1B-55K dimers bound to the N termini of p53 tetramers. In support of this model, a p53 mutation that prevents tetramer formation greatly reduces E1B-55K-induced tethering in PML nuclear bodies and p53 nuclear export. These data indicate that E1B-55K's association with PML nuclear bodies inactivates p53 by first sequestering it in PML nuclear bodies and then greatly facilitating its nuclear export.
During adenovirus type 5 (Ad5) infection and oncogenic transformation of primary cells by E1A and E1B, E1B-55K protein inhibits the activity of cellular p53 (17, 82) , a major regulator of cell cycle arrest and apoptosis (11, 25, 76) , through multiple mechanisms (4, 7, 78) . Upon activation, p53 becomes localized in promyelocytic leukemia (PML) nuclear bodies (PML-nb), presumably to be activated by colocalized nuclear acetyltransferases (e.g., p300 and CBP) and kinases (e.g., HIPK2, ATR, and Chk2) through acetylation and phosphorylation, respectively (5, 14, 23, 46) . PML-nb are dynamic, heterogeneous macromolecular multiprotein networks ϳ1 m in diameter found in the nuclei of mammalian cells. There are 1 to 30 PML-nb per nucleus (5, 46) . They recruit and release a number of proteins to facilitate several different nuclear processes, such as apoptosis, senescence, tumor suppression, and antiviral defenses.
Many of the proteins associated with PML-nb, including several isoforms of PML, a major component of PML-nb required for their formation, are reversibly modified posttranslationally by conjugation to lysine ε-amino groups of small ubiquitin-like modifiers (SUMOs) (34, 75, 85) . This modification is important for their recruitment to PML-nb and consequently for the proper formation of the nuclear domain through noncovalent interactions between sumoylated proteins and proteins containing SUMO-interacting motifs (SIMs) (35, 42, 69) . SUMOs are added to specific proteins by an enzymatic pathway analogous to the protein ubiquitination pathway, with a single E1 SUMO-activating enzyme (the SAE1/SAE2 heterodimer in humans), a single E2 SUMO-conjugating enzyme (UBC9), and E3 SUMO protein ligases that direct the charged E2 to sumoylate specific lysines on specific target proteins (34, 66) . Modification of transcription factors by SUMO can have diverse effects, including targeting to subnuclear compartments (such as PML-nb) (34) and repression of transcriptional activity (51, 61, 81) . A remarkable aspect of this process is that the steady-state level of sumoylation of many transcription factors is often extremely low when repression is maximal, on the order of a few percent of the total cellular protein in question, probably because SUMO groups are rapidly removed after their addition (9, 34) .
During viral infection, E1B-55K is first observed in PML-nb (19, 48) , where it associates with p53 (52) . It was recently reported that E1B-55K can stimulate sumoylation of p53 in vivo when the two proteins are overexpressed by transient transfection (57) , and it is well established that many proteins associated with PML-nb are sumoylated or interact with sumoylated proteins through noncovalent interactions (34, 35, 42, 69) . Thus, we examined the relationship between E1B-55K association with PML-nb and the mechanism by which E1B-55K represses p53 transcriptional activity (82) and stimulates p53 nuclear export to aggresomes, as observed in cells stably transformed by Ad5 (8, 52, 83) . We show, using recombinant purified proteins required for SUMO1 modification, that E1B-55K is a novel E3 SUMO1 p53 ligase in vitro. We report that in vivo during viral infection, E1B-55K induces the low level of p53 sumoylation typically observed for sumoylated transcription factors (34) . We find that p53 becomes colocalized to PML-nb with E1B-55K upon the expression of E1B-55K in the absence of other viral proteins. We report that SUMO modification of p53 contributes to maximal repression of p53 transcriptional activation function by E1B-55K. Using fluorescence recovery after photobleaching (FRAP) of p53-YFP (yellow fluorescent protein), we report that E1B-55K tethering of p53 in PML-nb greatly restricts p53 nuclear mobility in living cells and that E1B-55K-induced SUMO1 modification of p53 results in an increase in the stability of p53's association with PML-nb. These results indicate that E1B-55K's association with PML-nb inactivates p53 by first sequestering it in PML-nb and then greatly facilitating its nuclear export. 
MATERIALS AND METHODS

Cell and virus culture, transient transfection luciferase reporter assays, and Western blotting. A549 (p53
, and 293 (transformed with Ad5 E1A and E1B) (68) cells were cultured in Dulbecco's modified Eagle medium supplemented with penicillin-streptomycin-glutamine and 10% fetal bovine serum (Invitrogen Life Technologies). Ad5 mutants E4inORF3/dl355* (37) and 3112 (E1B-55K Ϫ E4orf3 Ϫ ) (70) were propagated in 293 cells and assayed by plaque formation. For transfection luciferase assays, H1299 p53 Ϫ cells were plated onto 60-mm tissue culture plates 12 h before transfection with Lipofectamine 2000 (Invitrogen Life Technologies) according to the manufacturer's protocol using 100 ng of the p21-luc reporter (a gift from Xuan Liu, University of California Riverside), 100 ng of Rluc (Promega), 200 ng of pcDNA3 expression vector for p53, p53K386R, or p53K386R with K-to-R mutations in additional lysines as indicated, and 800 ng of pSR␣ vector for E1B-55K or empty vector (82) . Firefly luciferase activity was assayed and normalized to Renilla luciferase using the Promega dual-luciferase assay system. Western blotting for E1B-55K and p53 was done with monoclonal antibodies (MAbs) 2A6 (67) and D0-1 (sc-126), respectively.
Detection of SUMO-p53 in infected and transfected cell extracts. Two 150-mm plates of A549 cells at 80% confluence were infected with the indicated Ad5 mutants, and cell extracts were prepared at 20 h postinfection (hpi). Cells were washed twice in phosphate-buffered saline (PBS) with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 2 mM N-ethylmaleimide (NEM), extracted with 1 ml 5% sodium dodecyl sulfate (SDS) lysis buffer (5% SDS, 30% glycerol, 150 mM Tris [pH 6 .7], 20 mM NEM, 1 mM PMSF, 2ϫ Roche Complete EDTA-free protease inhibitor), and sonicated. Extract from 2.4 ϫ 10 7 cells was subjected to immunoprecipitation by dilution of the SDS lysis buffer to final concentrations of 0.5% SDS, 1% Triton X-100, 150 mM NaCl, 50 mM Tris (pH 7.4), 1 mM EDTA, 1 mM PMSF, 3 mM NEM, and 1ϫ Roche Complete EDTA-free protease inhibitor. The diluted samples were subjected to preclearing with rabbit IgG (sc-2345) conjugated to agarose for 2 to 4 h at 4°C, followed by centrifugation and removal of the supernatant, which was then subjected to immunoprecipitation with ABCAM rabbit antiserum ab11672 to human SUMO1 bound to eBioscience Rabbit True Blot beads or rabbit IgG conjugated to agarose (sc-2345) at 4°C overnight (ϳ15 h) in Bio-Rad chromatography columns with nutation. Alternatively, the diluted SDS lysis buffer was subjected to preclearing with Santa Cruz mouse IgG conjugated to agarose (sc-2343), followed by immunoprecipitation as described above with anti-p53 MAb D0-1 coupled to agarose (sc-126 AC). The immunoprecipitates were washed twice in 150 mM NaCl-50 mM Tris (pH 7.4)-1 mM EDTA-1% Triton X-100, twice in 150 mM NaCl-50 mM Tris (pH 7.4), and once with 300 mM NaCl-100 mM Tris (pH 7.4). Immunoprecipitates were dissolved in 3ϫ SDS gel loading buffer and heated to 100°C for 10 min. Fifty percent of the immunoprecipitates were resolved by 8% Tris-glycine polyacrylamide gel electrophoresis (PAGE). Western blotting detection of p53 was with MAb D0-1 (sc 126), detection of hSUMO1 was with ABCAM ab11672, and detection of SUMO2 and/or SUMO3 was with anti-SUMO2/3 MAb (84), a gift from Michael Matunis, Johns Hopkins University.
For assays of transfected H1299 and A549 cells, cells were transfected using Lipofectamine 2000 (Invitrogen Life Technologies) according to the manufacturer's protocol. H1299 cells in 10-cm plates were transfected with 8 g pSR␣E1B-55K plus 8 g pcDNA3-p53-YFP (a gift from Xuan Liu, University of California Riverside), pcDNA3-p53K386R-YFP (see Fig. 1d ), pcDNA3-p53, pcDNA3-p53K386R, or pcDNA3-p53K386R plus additional K-to-R mutations (see Fig. 5 ). At 24 h posttransfection, cells were lysed and subjected to immunoprecipitation by the protocol for detection of SUMO-p53 in infected-cell extracts described above or cell lysates were subjected to Western blotting without prior immunoprecipitation.
In vitro sumoylation assay. His-myc-SUMO1, his-hUBC9, hSAE1 (with the N-terminal 10 amino acids deleted to improve expression), and His-hSAE2 were all expressed in Escherichia coli. (The His-SAE2 vector was a gift from Frauke Melchior, Max Planck Institute of Biochemistry.) His-tagged recombinant proteins were purified by Ni 2ϩ -nitrilotriacetic acid (NTA) column chromatography. A 10ϫ SUMO cocktail of 0.46 mM (6.2 mg/ml) his-myc-SUMO1, 6.9 M (0.85 mg/ml) E1, and 0.11 mM (2.2 mg/ml) his-hUBC9 in 5 mM Tris (pH 7.5), 25 mM NaCl, 5 mM ␤-mercaptoethanol, and 50% glycerol was used. E1B-55K-His 6 was purified from baculovirus vector-infected sf9 cells as described previously (26) . Recombinant p53 was purchased from Active Motif. Sumoylation reaction mixtures of 20 l containing 50 mM Tris (pH 8), 5 mM MgCl 2 , 5 mM ATP, 2 mM dithiothreitol (DTT), 12.5 ng p53, 2 l 10ϫ SUMO cocktail, and the indicated amount of E1B-55K were incubated for 40 min at 30°C.
Immunofluorescence microscopy. Standard immunofluorescence microscopy without confocal imaging was performed as described previously (52) . For confocal immunofluorescence microscopy, H1299 cells were plated on sterile 22-by-22-mm coverslips in six-well dishes preincubated with 25 g/ml fibronectin (Sigma catalog no. F1141-1MG) for 15 min and washed with PBS. Cells were transfected with Lipofectamine 2000 using 200 ng pcDNA3-p53-YFP or p53K386R-YFP and 800 ng pSR␣E1B-55K where indicated 24 h before fixation with 2% formaldehyde for 15 min at room temperature or overnight at 4°C, washed with PBS, permeabilized in PBS plus 1% Triton X-100 for 15 min, rinsed three times in PBS plus 0.1% Tween 20, and incubated for 30 to 40 min in PBS-5% bovine serum albumin (BSA)-1% Tween 20. Coverslips were then incubated for 1 h at room temperature in primary antibody diluted in PBS-5% BSA-1% Tween 20 and then incubated for 5 min with each of four successive washes of PBS plus 0.1% Tween 20. Slides were then incubated for 1 h in the dark in secondary antibody diluted in PBS plus 0.1% Tween 20, washed four times for 5 min each in PBS plus 0.1% Tween 20, stained with 0.5 g/ml 4Ј,6-diamidino-2-phenylindole (DAPI) for 10 to 15 min, rinsed with PBS, and mounted onto slides using Vectashield mounting medium (Vector Laboratories, catalog no. H-1400). MAb 2A6 was used as the primary antibody against E1B-55K with a secondary Texas Red donkey anti-mouse IgG (715-075-150) from Jackson ImmunoResearch Labs (false colored green). The primary antibody for PML was goat anti-PML (sc-9862) with a secondary Cy3 donkey anti-goat IgG (705-165-147) from Jackson ImmunoResearch Labs (false colored red). Confocal fluorescence microscopy was with a Leica TCS SP2 AOBS single-photon confocal microscope using a 63ϫ 1.4 numerical aperture oil immersion objective.
FRAP. H1299 cells were transfected as described above for immunofluorescence microscopy. The microscope stage and objective were placed in an enclosed chamber preequilibrated to 37°C with a continuous flow of 5% CO 2 over the microscope stage. The laser settings were fly mode at 1,000 Hz, 8ϫ zoom, and an image format of 512 by 256. Fluorescence emission from enhanced YFP was detected with the range of photomultiplier tube 2 set to 525 to 600 nm (with a maximal gain of 680). Bleaching of a 3-m-diameter circle was performed with laser lines 405, 458, 488, and 514 nm set to maximal power. The average frame rate for prebleaching (10 frames), bleaching (4 frames), and initial postbleaching (16 frames) was 1 frame/0.208 s. The frame rates for additional postbleaching imaging were 30 frames (1 frame/4 s), followed by 50 frames (1 frame/10 s) for monitoring of longer recovery times. Additional experiments were performed with different settings to show that recovery rates were similar independent of the laser lines used for bleaching or the times used for data collection postbleaching. The settings for these experiments were fly mode at 1,000 Hz, 8ϫ zoom, an image format of 512 by 256, and an averaging of 2. Fluorescence emission from YFP was the same as that described above. Bleaching of a 3-m-diameter circle was performed with laser line 514 nm only set to maximal power. The frame rate for prebleaching (5 frames), bleaching (3 or 4 frames), and postbleaching (2 frames) was 1 frame/0.416 s). The frame rates for additional postbleaching imaging were 30 frames (1 frame/3 s) and 60 frames (1 frame/6 s) or 30 frames (1 frame/3 s) and 100 frames (1 frame/6 s) for monitoring of long recovery times.
Separate FRAP experiments were performed for each construct as indicated, and then the normalized fluorescence from each time point was averaged to generate a single FRAP curve: p53-YFP only (n ϭ 3 experiments), p53-YFP and E1B-55K (n ϭ 4 experiments), p53-YFP and PML-IV (n ϭ 3), p53-YFP with PML-IV and E1B-55K (n ϭ 7), p53K386R-YFP with PML-IV and E1B-55K (n ϭ 12), and p53L344P-YFP and E1B-55K (n ϭ 4). Analyses were performed on two or three separate transfections per construct. Average background values were determined outside cells (region of interest 2 [ROI 2 ]) and subtracted from all of the raw data points of the bleach region (ROI 1 ), as well as inside the nucleus outside the bleach area (ROI 3 ) before further analysis as follows (62): B n ϭ (ROI 1 Ϫ ROI 2 )/(ROI 3 Ϫ ROI 2 ), P b ϭ average of prebleach signal calculated in B n , and normalized fluorescence intensity (FI N ) ϭ B n /P b . These data were then normalized based on the bleach depth, generating curves set to zero (based on the first point after bleaching) to the prebleach intensity, calculated as follows:
The time starting at the first point postbleaching was set to time zero. Recovery curves report both on the exchange of bound molecules and on the faster exchange of unbound molecules in the bleached volume and are therefore biphasic and must be fitted by a double-exponential equation. Equations were derived from reference 71 and references therein as follows:
, where A is the amplitude of the fast phase and B is the amplitude or plateau of recovery of the slow phase, t is time, and k 1 and k 2 are the rate constants for the fast and slow phases of recovery, respectively, derived from curve fitting with Kaleidagraph software. Half-times of recovery were calculated from the fitted rate constants as follows: t 1/2 ϭ ln 0.5/Ϫk. The t 1/2 reported always represents the slow phase from a double-exponential fit. The data averaging for constructs expressing p53-YFP with PML-IV and E1B-55K were noisy after 180 s, and that for p53K386R-YFP with PML-IV and E1B-55K were noisy after 350 s due to cell movement. Therefore, reported half-times for these constructs were estimated based upon extrapolation of data to full recovery.
Gel filtration analysis of E1B-p53 complex. Samples of 1.5 g of purified rE1B-55K and 1.5 g of purified p53 (Active Motif) were incubated separately or together at room temperature for 30 min in 300 mM KCl-20 mM HEPES (pH 7.4)-1 mM DTT-0.2 mM EDTA-20% glycerol. The three samples then were separately subjected to gel filtration on a 10-ml Superose 6 column in the same buffer. Fractions of 0.5 ml were collected, and fractions 10 to 37 were subjected to trichloroacetic acid precipitation and analyzed by Western blotting. Dextran blue 2000 eluted in fraction 10 (the void volume), and the peak of thyroglobulin (669 kDa) eluted in fraction 21.8, that of ferritin (440 kDa) eluted in fraction 25.4 , that of alcohol dehydrogenase (150 kDa) eluted in fraction 28, and that of BSA (68 kDa) eluted in fraction 32.
RESULTS
E1B-55K stimulates sumoylation of p53 during viral infection. Muller and Dobner (57) reported that transfection of p53 Ϫ H1299 cells with expression vectors for p53 and Ad5 E1B-55K resulted in p53 conjugation to SUMO1, in contrast to H1299 cells transfected with a p53 expression vector alone. To determine if E1B-55K also stimulates p53 sumoylation during Ad5 infection at the normal cellular concentrations of the proteins involved, we assayed this modification of p53 in extracts from virus-infected p53 ϩ A549 cells by immunoprecipitation, followed by Western blotting. When both E1B-55K and E4orf6 are expressed, they assemble with components of the cellular cullin 5 class of E3 ubiquitin ligases to form a multisubunit ubiquitin ligase that polyubiquitinates p53 (33, 63) , leading to its proteasomal degradation (64, 73) . Consequently, to observe modified versions of p53 induced by Ad5 infection, we infected cells with viruses mutant in the viral E1B-55K or E4orf6 protein required for formation of the viral ubiquitin ligase. Cell extracts were prepared under conditions (5% SDS, 20 mM NEM) that potently inhibit the high activities of desumoylating enzymes present in cell extracts. We observed p53 sumoylation during viral infection most consistently in cells infected with Ad5 mutant in E4orf6 and E4orf3 (E4inORF3/ dl355* [37] , Fig. 1a , bottom, and b). During infection with wild-type (WT) Ad5, E4orf3 is localized to PML-nb along with E1B-55K (48) . Mutation of E4orf3 may have increased the ability to detect sumoylated p53 during infection because sumoylated proteins are enriched in PML-nb and the period of association with PML-nb during viral infection of another E1B-55K bound host cell protein, MRE11, is greatly increased by mutation of E4orf3 (52) .
A549 cells infected with an E4orf3 E1B-55K double mutant, 3112 (70) , accumulated p53 to levels similar to those observed following infection with a E4orf3 E4orf6 double mutant (Fig.  1a, top) because of the inability of each of these mutants to generate the viral ubiquitin ligase that requires both E1B-55K and E4orf6 and polyubiquitinates p53, targeting it for proteasomal degradation (33, 63) . But in the E4orf3 Ϫ background, the level of SUMO1-modified p53 was clearly higher in the E1B-55K ϩ mutant than in the E4orf6 ϩ mutant (Fig. 1a and b) . Immunoprecipitation with anti-p53, followed by Western blotting with either anti-SUMO1 antibody or a MAb that recognizes both of the other two closely related major human SUMOs, SUMO2 and SUMO3 (84) , showed an E1B-55K-induced increase in p53 conjugation to SUMO1, but not to SUMO2 or SUMO3 (Fig. 1b and c) . Infection with both mutant viruses increased the level of SUMO2/3-modified p53 to an extent similar to that seen in mock-infected cells. These results indicate that, in addition to E1B-55K's ability to stimulate SUMO1 modification of p53 in transfected cells (57), E1B-55K can also stimulate p53 sumoylation during viral infection at the normal cellular concentrations of all of the components involved in the process. As for other sumoylated transcriptional regulators, the low level of SUMO1-p53 observed in virus-infected cells was probably a consequence of transient sumoylation resulting from the rapid removal of SUMO1 shortly after its addition (9, 34) .
Experiments (described below) using fluorescence microscopy techniques were performed with a p53-YFP fusion. To determine if E1B-55K induces sumoylation of p53-YFP comparably to p53 not fused to YFP, expression vectors for p53-YFP and E1B-55K were cotransfected into p53 Ϫ H1299 cells. Twenty-four hours posttransfection, whole-cell extracts were prepared under conditions that prevent the loss of SUMO1 from SUMO1-modified proteins and analyzed by Western blotting with an anti-p53 MAb. A band with the mobility expected for p53-YFP conjugated to endogenous cellular SUMO was observed (Fig. 1d , lane 2). That this band corresponds to SUMO1-modified p53 was demonstrated by the observation of a band with the same mobility detected following immunoprecipitation with anti-p53 MAb and Western blotting using SUMO1-specific antibody (lane 8). Further, a doublet near this position was observed when expression vectors for FLAGtagged SUMO1 and E1B-55K were cotransfected with the YFP-p53 expression vector (Fig. 1d, lane 4) . When extract from these cells was immunoprecipitated with anti-p53 MAb and Western blotted with an anti-Flag MAb, the upper band of this doublet was shown to correspond to p53-YFP conjugated to Flag-tagged SUMO1 (lane 10). We conclude that E1B-55K stimulates conjugation of p53-YFP to SUMO1 as it does for untagged p53 in Ad5-infected cells (Fig. 1a to c) and in transiently transfected cells (57) . Moreover, the fraction of p53-YFP sumoylated (Fig. 1d , lane 2) was similar to that reported for p53 in a comparable cotransfection experiment (57) and as measured quantitatively (Fig. 1e) .
The p53 protein contains a single previously determined site of sumoylation in a SUMO site consensus sequence at K386 (KXE, where is a hydrophobic amino acid and X is any amino acid) (30, 65) . Nonetheless, we observed that p53K386R-YFP mutated at this site continued to be sumoylated in transfected cells, although the extent of sumoylation was reduced compared to that of WT p53-YFP (Fig. 1d , lane 6). To quantitate the difference in the extent of E1B-55K-induced sumoylation of p53 and p53K386R, extracts from p53 Ϫ H1299 cells transfected with expression vectors for these proteins were subjected to serial 2-fold dilutions and Western blotting with anti-p53 MAb (Fig. 1e) . The intensity of the signal observed for SUMO1-p53 after four 2-fold serial dilutions was similar to the intensity of unmodified p53 detected on the same Western blot after 10 2-fold dilutions, indicating that the fraction of SUMO1-modified p53 at steady state was 2 Ϫ10 / 2 Ϫ4 , about 1.5%. The intensity of the signal observed for SUMO1-p53K386 after 3 2-fold serial dilutions was similar to the intensity of unmodified p53K386R after 10 2-fold dilutions, indicating that the fraction of SUMO1-modified p53K386R was about 0.8%. A similar fraction of SUMO1 conjugation was observed for p53-YFP and p53K386R-YFP (data not shown).
E1B-55K is a SUMO1 E3 ligase for p53. Since E1B-55K stimulates p53 sumoylation in vivo in transiently transfected and Ad5-infected cells, we hypothesized that E1B-55K may function as a SUMO1 E3 ligase and tested for this activity in vitro. We used E. coli-produced, purified human His 6 -myc- Ϫ ) cells were transfected with the indicated expression vectors, and whole-cell extract was prepared after 24 h and Western blotted with anti-p53 (lanes 1 to 6). In lanes 7 to 10, extracts were immunoprecipitated with anti-p53 MAb and the IP was Western blotted with anti-SUMO1 (7, 8) or anti-Flag (9, 10) . (e) H1299 cells were transfected with expression vectors for E1B-55K and p53, whole-cell extract was prepared at 24 h posttransfection, 2-fold dilutions were run in neighboring lanes of an SDS gel, and the gel was subjected to Western blotting with anti-p53 MAb. Arrowheads indicate bands of p53-SUMO1 and p53 of comparable intensities.
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SUMO1 (recombinant SUMO1 [rSUMO1]), SAE1/His 6 -SAE2 (rSAE1/SAE2, human SUMO E1), His 6 -UBC9 (rUBC9, human SUMO E2), recombinant p53, and baculovirus vector-produced, purified E1B-55K-His 6 (rE1B-55K). Addition of rE1B-55K stimulated ligation of rSUMO1 to recombinant p53 in proportion to the amount of rE1B-55K added (Fig. 2a) . Thus, this E1B-55K preparation had E3 SUMO1 ligase activity for p53. The stimulation of p53 sumoylation produced by E1B-55K was not due to a contaminating activity from insect cells, since eliminating rE1B-55K, E1 (rSAE1/ SAE2), or E2 (rUBC9) eliminated the stimulation of p53 sumoylation observed in the complete system (Fig. 2b) . Also, a control protein fraction prepared from sf9 cells infected with an empty baculovirus vector prepared in parallel with a second preparation of rE1B-55K had no SUMO1-p53 ligase activity (Fig. 2c) . The very low level of SUMO1-p53 observed in the control lane and lane 3 of Fig. 2b was due to the ability of UBC9 to direct a very low level of sumoylation in vitro at a
The indicated amount of baculovirus-expressed Ad2 E1B-55K-His 6 purified by Ni 2ϩ -NTA column chromatography as described previously (55) (rE1B-55K) was incubated at 30°C for 40 min in sumoylation buffer (including ATP) plus purified, E. coli-expressed, Myc-tagged human SUMO1, human SAE1/SAE2 (SUMO E1), human UBC9 (SUMO E2), and human p53 (r p53) for 40 min at 30°C. Reaction products were analyzed by Western blotting with anti-p53 MAb. (b) Two-hundred-nanogram samples of recombinant E1B-55K (rE1B-55K), rSUMO1-Myc, recombinant p53, SUMO E1 (rSAE1/SAE2), and SUMO E2 (rUBC9), as indicated (ϩ, Ϫ), were incubated and analyzed as described for panel a. (c) A second preparation of rE1B-55K (ϳ100 g/ml) was prepared in parallel with a control protein fraction from sf9 cells infected with the empty baculovirus vector and taken through the same purification steps. BSA (100 g/ml) was added to the final control fraction, and 2 l of each was added to reaction mixtures containing the other components shown in panel b. consensus sumoylation site in the absence of an E3 SUMO ligase (34) .
To further test if the rE1B-55K purified from insect cells was associated with a contaminating insect cell activity that stimulated p53 sumoylation, we purified the rE1B-55K protein fraction further by gel filtration chromatography on a Superose 6 column. Column fractions analyzed by SDS-PAGE and silver staining (Fig. 2d) and Western blotting (Fig. 2e) revealed elution of E1B-55K as expected for the dimer of native E1B-55K (54), with a peak in fractions 28 to 31. In vitro p53-SUMO1 ligase activity of each column fraction was assayed with E. coli-expressed recombinant E1, E2, Myc-tagged SUMO1, and recombinant p53. A peak of p53-SUMO1 E3 ligase activity coeluted with the peak of rE1B-55K in fractions 28 to 31 as assayed by Western blotting with anti-p53 (Fig. 2f ) and antiMyc (Fig. 2g) MAbs. This activity did not coelute with two polypeptides of ϳ65 and ϳ75 kDa that peaked in fraction 28 as detected by silver staining at much weaker intensity than the E1B-55K band or the weakly staining band of ϳ30 kDa eluting in fractions 29 to 33 but rather followed the elution profile of the peak of rE1B-55K. If the p53-SUMO1 activity detected in Fig. 2a had been due to a complex formed by rE1B-55K and insect cell SUMO1 E3 or E2, the activity would have eluted at a higher molecular weight than the peak of rE1B-55K in fractions 28 to 31. This coelution on a gel filtration column of p53-SUMO1 E3 ligase activity with rE1B-55K detected by protein staining demonstrates that the activity is intrinsic to E1B-55K.
E1B-55K tethers p53 in PML-nb. To address the question of whether E1B-55K inactivates p53 in part by tethering it in PML-nb, we analyzed the influence of E1B-55K on the intranuclear mobility of p53-YFP in living cells by FRAP, a well-established method for determining the stabilities of macromolecular interactions in vivo (20) . H1299 cells (p53 Ϫ ) were transfected with an expression vector for p53-YFP plus or minus an E1B-55K expression vector. First, we analyzed the subcellular localization of these proteins, as well as PML, the principal cellular component of PML-nb, by confocal microscopy of fixed cells 24 h after transfection. Direct detection of YFP fluorescence and immunostaining with anti-PML antibody (red) and anti-E1B-55K MAb (green) allowed the visualization of all three proteins in the same cells (Fig. 3a to c ). Nuclei were visualized by staining with DAPI. In the absence of E1B-55K, p53-YFP was distributed throughout the nucleoplasm and did not colocalize with PML in PML-nb (Fig. 3a) . When E1B-55K was coexpressed with p53-YFP, in ϳ50% of the cells, p53-YFP was colocalized with E1B-55K and endogenous PML in structures with a size and morphology typical of PML-nb, as well as in cytoplasmic inclusions with E1B-55K (Fig. 3b) . In ϳ5% of the cells, p53-YFP and E1B-55K colocalized with PML in PML-nb but no cytoplasmic p53-YFP was observed. In ϳ45% of the cells, p53-YFP was observed only in large cytoplasmic inclusions bodies with E1B-55K (see Fig. 6e ). By 48 h posttransfection, p53-YFP was observed only in cytoplasmic inclusions with E1B-55K in ϳ65% of the cells. In the absence of a cotransfected expression vector for p53-YFP, at 24 h posttransfection, E1B-55K colocalized with PML-nb in ϳ50% of the cells, demonstrating that p53 is not required for E1B-55K association with these subnuclear domains in p53 Ϫ H1299 cells (data not shown). The relative amounts of PML, E1B-55K, and p53-YFP in these nuclear foci varied, so that the overlay of all three colors (Fig. 3b) produced foci with different shades of color from red (mostly PML) to green (mostly E1B-55K) to yellow (mixtures of the three proteins). But the vast majority of p53-YFP foci in nuclei colocalized with both PML and E1B-55K. The E1B-55K-induced p53-YFP association with PML-nb requires direct binding of E1B-55K to p53 since it was not observed with a YFP fusion to p53 with a single amino acid substitution that inhibits E1B-55K binding (P27Y [50] ) (Fig. 3c) . Note that E1B-55K continued to associate with PML-nb in the absence of an interaction with P27Yp53. As in the case of cells coexpressing WT p53-YFP and E1B-55K (Fig.  3b) , the relative amounts of PML and E1B-55K in these nuclear foci varied, so that the overlay produced foci with different shades of color from red (mostly PML) to green (mostly E1B-55K) to yellow (equal staining of PML and E1B-55K). But the vast majority of E1B-55K foci in nuclei colocalized with PML (Fig. 3c) .
During adenovirus infection, E1B-55K first appears in PML-nb (19, 48) . In cells infected with an E4orf6 mutant where p53 is stabilized, p53 first accumulates with E1B-55K in PML-nb at 8 to 12 hpi, before it is observed in cytoplasmic inclusions in an increasing fraction of cells following 16 hpi (52) . Consequently, we interpret E1B-55K and p53-YFP in PML-nb (Fig. 3b) to be intermediates in the nuclear export of E1B-55K-p53-YFP complexes. As discussed below, consistent with this interpretation, we found that in transfected p53 ϩ A549 cells, E1B-55K mutated in its sumoylation site was greatly inhibited both in associating with PML-nb and in stimulating p53 nuclear export.
To analyze the dynamics of p53-YFP association with PML-nb directly, we analyzed the mobility of p53-YFP in living cells by FRAP. The t 1/2 for fluorescence recovery of nucleoplasmic p53-YFP expressed alone was ϳ1 s (Fig. 3d and e, black circles). This is similar to the t 1/2 of other nucleoplasmic proteins and indicates very rapid mobility throughout the nucleoplasm for the free transcription factor (29) . Coexpression of E1B-55K led to the appearance of most of the p53-YFP in nuclear foci in living cells (Fig. 3d, prebleach) , presumably associated with PML-nb, as observed in fixed and immunostained transfected cells (Fig. 3b) . FRAP of p53-YFP in these foci revealed a reproducible t 1/2 of ϳ85 s. Consequently, the E1B-55K-induced association of p53-YFP with PML-nb decreased the mobility of p53-YFP in the nucleus by nearly 2 orders of magnitude. This tethering of p53 in PML-nb likely makes a significant contribution to the inhibition of p53 transcriptional activation function by E1B-55K (82) by restricting its ability to interact with p53-binding sites in target gene control regions.
E1B-55K-induced SUMO1 modification of p53 contributes to p53 tethering in PML-nb and to inhibition of p53 transcriptional activation function. To determine if the low level of p53-SUMO1 modification induced by E1B-55K contributes to E1B-55K-induced tethering of p53 in PML-nb, we used FRAP assays to compare the tethering of WT p53-YFP and p53K386R-YFP. This mutation of the previously determined site of p53 sumoylation at a SUMO modification consensus sequence (30, 65) did not eliminate the low steady-state level of p53 conjugation to SUMO1 induced by E1B-55K (57) but decreased it by a factor of ϳ2 (Fig. 1e) . The influence of this decrease in the steady-state level of p53-SUMO1 modification on tethering in PML-nb was most apparent in cells in which tethering was increased further by overexpression of the isoform of PML that binds p53. There are several PML isoforms expressed from alternatively spliced PML mRNAs (38) . p53 interacts with isoform PML-IV, and transfection of a PML-IV expression vector causes p53 to become partially colocalized with PML-nb (6, 24) . Consistent with these observations, we also observed partial colocalization of p53-YFP with PML-nb in H1299 cells cotransfected with expression vectors for p53-YFP and PML-IV and an increase in the t 1/2 of p53-YFP from ϳ1 s (Fig. 3e) to ϳ15 s in the presence of overexpressed PML-IV (Fig. 3f) . When E1B-55K was coexpressed with p53-YFP and PML-IV, the t 1/2 of p53-YFP was decreased further to ϳ250 s (Fig. 3f) . In contrast, the t 1/2 of p53K386R-YFP in H1299 cells cotransfected with vectors for PML-IV and E1B-55K was ϳ80 s. Consequently, under these conditions, a decrease in the steady-state level of SUMO1 conjugation to p53 from 1.5% for WT p53-YFP to 0.8% for p53K386R-YFP led to an ϳ3-fold decrease in the stability of the E1B-55K-induced association of p53 with PML-nb. These results indicate that E1B-55K-induced sumoylation of p53 contributes to the E1B-55K-induced sequestration of p53 in PML-nb.
To analyze the influence of the reduced level of p53K386R sumoylation on the ability of E1B-55K to repress the activation function of p53, we performed luciferase reporter assays with p53 Ϫ H1299 cells. The K386R mutation generated ϳ120% of the luciferase activity induced by the transfection of an equal amount of expression vector for WT p53 from a cotransfected reporter with the p21 CIP control region. To compare the extent of repression by a cotransfected E1B-55K expression vector, we normalized the level of luciferase activity induced by WT p53 and p53K386R to 1 and plotted the normalized activity of luciferase in cells with coexpressed E1B-55K (Fig. 4a) . In six independent transfection assays performed on 3 separate days, we observed a reproducible decrease in the extent of E1B-55K repression of p53K386R compared to that of WT p53. This is consistent with the reduced tethering in PML-nb of p53K386R-YFP compared to that of WT p53-YFP (Fig. 3f) .
E1B-55K induces sumoylation at multiple lysines in mutant p53K386R. These data support a model for maximal repression of p53 that requires E1B-55K-induced sumoylation at p53 lysine 386, which helps tether p53 at PML-nb in the presence of E1B-55K. We postulated that if one could abolish sumoylation of p53 completely, this might further decrease E1B-55K-mediated inhibition of p53 transcriptional activity. Therefore, we made mutations of every additional lysine in p53 in combination with the K386R mutant to determine if we could map a second sumoylation site in p53 that continued to be sumoylated in the p53K386R mutant. There are a total of 20 lysines in p53. Using the K386R-p53 mutant construct as a template, we made single or multiple mutations of all of the other lysines in p53, as shown in Fig. 5a . For simplicity, each construct was labeled for the new mutation but also contained the K386R mutation; K24R was K24R plus K386R-p53, etc. We transfected H1299 p53 Ϫ cells with expression vectors for E1B-55K and each of these p53 mutants with arginine substitutions for two or more lysines, prepared lysates under conditions that prevent desumoylation, and performed Western blotting using anti-p53 MAb on 2-fold serial dilutions of the lysates (Fig. 5b) .
For each construct, a band at the position of SUMO1-p53 was evident, although a smaller fraction of mutant K132R K139R K386R was sumoylated compared to the other mutants and therefore required a longer exposure of the Western blot to CIP promoter luciferase reporter and expression vectors for the indicated proteins, and luciferase activity in extracts was determined at 24 h posttransfection. Luciferase expression induced by p53K386R was reproducibly ϳ20% higher than for WT p53 in the absence of E1B-55K. In these plots, luciferase activities for WT p53 and p53K386R in the absence of E1B-55K were normalized to 1.0 to facilitate comparison of E1B-55K inhibition of transcriptional activation by p53 and p53K386R. Error bars indicate the standard deviation of the mean for six independent assays. (b) Luciferase activity induced by expression vectors for the indicated p53 mutants, normalized to expression of Renilla luciferase from a cotransfected expression vector. Except for the K386R mutant p53 protein, each of the mutant p53 proteins included the K386R mutation and mutations in the additional lysines indicated. ϩE1B-55K indicates cotransfection with the E1B-55K expression vector. The 6KR mutant protein contains mutations K370R, K372R, K373R, K381R, K382R, and K386R.
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reveal a band of this mobility clearly. A vector for p53 mutated in the six C-terminal lysines was also prepared (6KR, with the K370R, K372R, K373R, K381R, K382R, and K386R mutations). This mutant was also modified to an extent similar to that of the K386R single mutant (Fig. 5b) . Therefore, there is no major single secondary sumoylation site in p53 when K386 is mutated; E1B-55K can induce sumoylation of p53 at a variety of lysines. In this regard, E1B-55K is similar to the MDM2 p53 ubiquitin ligases that can polyubiquitinate p53 at a number of lysines (59) . Similarly, no single p53 lysine is required for human papillomavirus E6-induced p53 degradation (14a). Consequently, it was not possible to determine by mutagenesis of additional p53 lysines whether elimination of p53 sumoylation would further affect E1B-55K inhibition of p53 function over that observed for mutation of K386, the major site of p53 sumoylation identified previously (30, 65) . Each of these p53 double-or multiple-lysine mutants was assayed for the ability to activate luciferase expression from the p21-luciferase reporter and inhibition of this activity by cotransfection of the E1B-55K expression vector (Fig. 4b) . Each mutant stimulated luciferase expression at least as well as WT p53 or up to 2-fold more, with the exception of the K132R K139R K386R triple mutant. This is consistent with an earlier report that K132 is required for activation by p53 (14a). Since this mutant is sumoylated to a lesser extent than other p53 mutants (Fig. 5b) , it is possible that sumoylation or another modification of K132 is required for p53 activity. Activation by each of the active lysine double and multiple lysine-to-arginine mutants was inhibited by E1B-55K to a reduced extent compared to WT p53, comparable to the situation observed for p53K386R (Fig. 4b) .
Sumoylation of E1B-55K is required for its maximal association with PML-nb and efficient p53 nuclear export and inhibition. Although we were not able to eliminate sumoylation of p53 by mutation of multiple p53 lysines, mutation of the single known site of E1B-55K sumoylation at K104 within a typical sumoylation consensus sequence (VKRE) eliminates E1B-55K sumoylation and greatly inhibits its ability to repress transcriptional activation by p53 and therefore its ability to cooperate with adenovirus E1A in the transformation of primary baby rat kidney cells (22) . The K104R mutation also inhibits the ability of E1B-55K to stimulate SUMO1 conjugation to p53 (57) . The E1B-55K K104R mutation has also been reported to inhibit E1B-55K nuclear localization (22) . But since nuclear E1B-55K is associated with PML-nb (19, 48) (Fig. 3b) and mutation of the sumoylation site interferes with PML-nb association for many PML-associated proteins (34), we wondered if the failure to observe nuclear E1B-55K K104R might be due to its inability to associate with PML-nb rather than to a defect in nuclear import. WT E1B-55K is known to shuttle between the nucleus and cytoplasm (18, 45) , and mutation of its nuclear export signal (NES) leads to its association primarily with nuclear PML-nb (21) . Consequently, to determine if the E1B-55K K104R mutation influences the association of nuclear E1B-55K with PML-nb, we analyzed the subcellular localization of a double mutant in both the NES and the nearby sumoylation site at K104 (43) . This was done by confocal microscopy of transiently transfected p53 Ϫ H1299 cells with expression vectors for p53-YFP and an E1B-55K NES mutant (21) or the K104R mutant in the background of the NES mutation (43) (Fig. 6a and b) . As reported earlier (21) , mutation of the E1B-55K NES resulted in localization of the mutant E1B-55K to nuclear PML-nb, with no E1B-55K NES mutant in cytoplasmic inclusions in transiently transfected cells (Fig. 6a) . Results for the E1B-55K NES K104R double mutant were somewhat different than previously reported for A549 cells infected with an Ad5 mutant virus with this E1B-55K double mutation (43) . This is probably due to the absence of nuclear viral replication centers since, in virusinfected cells, E1B-55K moves from PML-nb to these replication centers once viral DNA replication commences (19, 60) . Also, E4orf3 expressed in virus-infected cells influences the subcellular localization of E1B-55K (1, 52) . In the absence of other viral proteins in the transiently transfected cells, the double mutant was localized throughout the cytoplasm and in large cytoplasmic inclusions similar to those formed by WT E1B-55K (Fig. 6b) . The double mutant also formed nuclear foci with bound p53. However, the NES K104R double mutant associated with PML-nb to a greatly reduced extent compared to the E1B-55K NES mutant (compare Fig. 6a and b) . This result is consistent with a requirement for E1B-55K sumoylation for efficient association with PML-nb, as observed for many PML-nb-associated sumoylated proteins (34) . Consistent results also were observed for E1B-55K and E1B-55K K104R in p53 ϩ A549 cells treated with the covalent inhibitor of exportin 1 (CRM1) required for nuclear export of WT E1B-55K (18, 45) (Fig. 6c) . A549 cells transfected with expression vectors for WT E1B-55K or E1B-55K K104R were treated with leptomycin B at 14 h posttransfection. When the Ϫ cells were transfected with expression vectors for p53-YFP and E1B-55K with a triple mutation in its previously mapped NES (21) . Cells were fixed, immunostained for the indicated proteins, and visualized by confocal microscopy as described in the legend to VOL. 84, 2010 E1B-55K IS A SUMO1-p53 E3 LIGASE THAT SEQUESTERS p53 IN PML-nb 12219 cells were fixed and immunostained for E1B-55K and PML (Fig. 6c, left) and for E1B-55K and p53 (Fig. 6c , right) at 24 h posttransfection and analyzed by standard fluorescence microscopy, WT E1B-55K was entirely localized to intranuclear foci together with PML and p53. In contrast, E1B-55K K104R was also primarily localized in nuclear foci with p53 (Fig. 6c , right) but most of these foci were not associated with PML (Fig. 6c, left) . When p53 ϩ A549 cells were transfected with expression vectors for WT E1B-55K or the E1B-55K K104R mutant in the absence of leptomycin B and stained for E1B-55K and p53, it was evident that WT E1B-55K induced the nuclear export of p53 far more efficiently than the E1B-55K K104R mutant that is inhibited from associating with PML-nb ( Fig. 6d and e) . These results imply that the E1B-55K K104R mutant fails to inhibit transcriptional activation by p53 (22) because it fails to associate with PML-nb where WT E1B-55K causes p53 to become sequestered ( Fig. 3b and d) . The results of Fig. 6d also imply that E1B-55K induction of p53 nuclear export is greatly enhanced by the interaction of E1B-55K with PML-nb.
An E1B-55K-p53 network contributes to p53 tethering in PML-nb. The E1B-55K NES K104R double mutant and p53-YFP in nuclei continued to colocalize in foci even when they were not associated with PML-nb (Fig. 6b) . Similarly, E1B-55K K104R localized to nuclei by treatment with leptomycin B colocalized in foci with endogenous p53 in A549 cells (Fig. 6c , right) even though most foci were not associated with PML-nb (Fig. 6c, left) . In considering what molecular interactions might cause such colocalization of p53 and E1B-55K in foci containing large numbers of proteins, we realized that p53, which is a tetramer (39), might form a network cross-linked by dimers of E1B-55K (54) which bind to the N-terminal activation domain region of each p53 monomer (40, 50) (Fig. 7a) . Since the p53 N-terminal regions extend from the p53 tetramerization domain with approximately tetrahedral symmetry (39), cross-linking of p53 tetramers by E1B-55K dimers might result in a three-dimensional lattice composed of multiple E1B-55K dimers and p53 tetramers (diagrammed in two dimensions in Fig. 7b ). This could explain the association of E1B-55K and p53 into large intranuclear foci in the absence of association with any other nuclear domain such as PML-nb, as observed for the E1B-55K NES K104R double mutant (Fig. 6b) and for E1B-55K K104R in leptomycin B-treated cells (Fig. 6c) .
To test the ability of E1B-55K and p53 to form high-molecular-weight complexes such as that diagrammed in Fig. 7b , we incubated purified E1B-55K and p53 in buffer with 0.3 M KCl either separately or together and analyzed the molecular sizes of any resulting complexes by gel filtration on a Superose 6 column (Fig. 7c) . E1B-55K incubated alone continued to elute with a peak near a globular protein marker of 150 kDa, as observed for the purified protein (54) . E1B-55K elutes ahead of the expected position of a globular protein the size of an E1B-55K dimer (110 kDa) because it has an extended conformation in solution, as revealed by its unexpectedly low sedimentation velocity (54) . p53 incubated alone eluted in a broad peak well ahead of globular proteins with the molecular mass of the p53 tetramer (ϳ200 kDa). This is the expected behavior during gel filtration of the highly extended p53 tetramer with random coil N-terminal and C-terminal domains (39) . However, when the two purified proteins were incubated together and subjected to gel filtration, molecular complexes eluting much earlier from the gel filtration column were observed, including in the void volume, corresponding to globular protein structures of Ͼ4 MDa (Fig. 7c) . These results are consistent with the formation of large molecular networks of the two proteins formed by the cross-linking of p53 tetramers by E1B-55K dimers, as diagrammed in Fig. 7b . Molecules of E1B-55K and p53 that did not shift in their elution on the gel filtration column may have been inactive for cobinding. But the observation that a significant fraction of E1B-55K and p53 did shift to high-molecular-weight fractions after coincubation indicates that the two highly purified proteins can form multiprotein complexes in vitro.
To determine the potential influence of such an E1B-55K-p53 network on the stability of p53 association with PML-nb, we used confocal microscopy and FRAP to characterize the interaction between E1B-55K and p53 with a point mutation, L344P, in its tetramerization domain that inhibits tetramer formation, resulting in p53 monomers (16) . p53L344P-YFP did not associate with PML-nb in transfected p53 Ϫ H1299 cells in the absence of coexpressed E1B-55K but was observed diffusely throughout the nucleoplasm (data not shown). Cotransfection of expression vectors for E1B-55K and p53L344P-YFP into H1299 cells resulted in association of the two proteins in PML-nb with larger diameters than observed for WT p53-YFP (Fig. 7d, compare to Fig. 3b) . In many cells, E1B-55K was concentrated on the surface of these enlarged PML-nb (Fig.  7d) , and this was occasionally observed for the p53L344P-YFP as well (data not shown). FRAP analysis revealed that the association of the mutant p53-YFP with PML-nb was reproducibly decreased from a t 1/2 of ϳ85 s for WT p53-YFP (Fig.  3e ) to a t 1/2 of ϳ10 s (Fig. 7e) . These results, together with the observation of high-molecular-weight complexes formed between the two purified proteins in vitro (Fig. 7c) , suggest that formation of a multiprotein network by cross-linking of p53 tetramers by E1B-55K dimers bound to their N termini contributes to the tethering of p53 in PML-nb by E1B-55K.
DISCUSSION
In cells infected with E1B-55K or E4orf6 mutant adenovirus, p53 accumulates to high levels (64, 73) (Fig. 1a) because it is stabilized and activated as a consequence of the abnormal activation of cell cycling induced by the adenovirus E1A proteins (53) . However, when E1B-55K and E4orf6 are both expressed, they assemble with subunits of the host cell cullin 5 class of E3 ubiquitin ligases (elongins B and C, cullin 5, Rbx1), substituting for their substrate-binding subunits and redirecting the cellular ubiquitin ligase to polyubiquitinate p53, inducing its recognition and degradation by proteasomes (33, 63, 64, 73) . This ubiquitin ligase activity is associated with an ϳ800-kDa complex that includes several other host cell polypeptides, including ␤-tubulin and microtubule-associated proteins (33) . This same ubiquitin ligase complex also targets the cellular MRN (MRE11-RAD50-NBS1) complex (74), a key regulator of the DNA double-strand break responses that both signals the occurrence of a double-strand break in DNA (13, 47) and functions, via the MRE11 subunit, as a nuclease in the initial steps of the repair process (36) . The same ubiquitin ligase complex also targets the cellular DNA ligase (DNA ligase IV) involved in the nonhomologous end-joining DNA repair pathway (2) . When this pathway is not inhibited by mutations in both E4orf6 and E4orf3 (10, 37, 74) , viral DNA replication is inhibited (2, 41) and viral DNA is ligated into concatemers that are too large to package (77) . The viral ubiquitin ligase also targets the integrin alpha 3 subunit, whose proteasomal degradation may promote release and spread of progeny virions (15) . The viral ubiquitin ligase also stimulates late viral gene expression by stimulating the nuclear export of late viral mRNAs (80) and by preventing an increase in PKR activity and subsequent eIF2␣ phosphorylation that occurs in cells infected with E1B-55K or E4orf6 mutants (72) , but the potential targets of proteasomal degradation involved in these processes are unknown.
While the complex of E1B-55K and E4orf6 with cellular cullin 5 ubiquitin ligase components leads to proteasomal degradation, and hence inactivation of p53, cellular transformation of primary cells by Ad2 and Ad5 generally results from integration of the viral E1A and E1B regions that map together near the left end of the viral genome, with exclusion of the E4 region (3). Transformation, which requires inhibition of apoptosis otherwise induced by activated p53, can occur in cells expressing only E1A and E1B-55K (17) because E1B-55K alone can inhibit p53 (82) , as well as MRN (52), function in the absence of their degradation.
An early observation regarding E1B-55K function was that it associates with PML-nb at early times after infection (19, 48) . As viral DNA replication commences, E1B-55K becomes associated with viral DNA replication centers (12, 19, 43, 48, 60) . However, E1B-55K remains associated with PML-nb if viral DNA replication is inhibited by infection with a mutant in the viral 72-kDA single-stranded DNA-binding protein (19) . Late in infection, E1B-55K also appears in cytoplasmic inclusions at the microtubule-organizing center (MTOC) with the properties of aggresomes (52) . Formation of E1B-55K-containing aggresomes requires transport to the MTOC on microtubules by dynein motors (52) , probably accounting for the association of ␤-tubulin and microtubule-associated proteins with the ϳ800-kDa complex containing the virus-induced p53 ubiquitin ligase activity in extracts prepared during the late phase of infection (33) . In cells infected with an E4orf6 mutant that cannot form the viral ubiquitin ligase, nuclear MRE11 first associates with E1B-55K in PML-nb and is subsequently exported to cytoplasmic aggresomes until virtually all of the cellular MRE11 appears in aggresomes in all of the cells (52) . Aggresomes assemble at the MTOC, where there is a high concentration of components of the ubiquitin-proteasomal degradation pathway (27, 44) . In WT Ad5-infected cells, where the viral ubiquitin ligase complex is formed, the E1B-55K-induced export of MRE11 to aggresomes stimulates the rate of MRE11 degradation since both inhibition of E1B-55K/MRE11 nuclear export by treatment with leptomycin B and disruption of cytoplasmic transport to the MTOC by treatment with nocodazole delay MRE11 degradation (52) . Changes in p53 subcellular localization through the course of infection with an E4orf6 mutant (where p53 is not degraded) are more complex than those observed for MRE11. When p53 first accumulates between 8 and 12 hpi, like MRE11, it associates with E1B-55K in PML-nb (52) , where E1B-55K first appears (19, 48, 52) . By 16 hpi, p53 is observed associated with E1B-55K in cytoplasmic aggresomes, as is MRE11 (43, 52) . However, p53 also remains associated with viral DNA replication centers in nuclei, along with E1B-55K (12, 52) . These results suggest that there are at least two classes of p53. One class that, like MRE11, first associates with E1B-55K in PML-nb and then is exported to cytoplasmic aggresomes in complex with E1B-55K and a second class that first associates with E1B-55K in PML-nb and then moves with E1B-55K to viral DNA replication centers and remains associated with these nuclear domains throughout infection. Also, during viral infection, E4orf6 decreases the association of E1B-55K with PML-nb and decreases E1B-55K sumoylation (49) .
The situation is less complicated in cells transfected with an Ad5 E1B-55K expression vector and in Ad5-transformed cells, where E1B-55K is expressed in the absence of viral DNA replication centers. In stably transformed cells, which express only viral proteins from E1A and E1B, nearly all of the cellular p53 becomes colocalized with E1B-55K in large cytoplasmic inclusion bodies (83) at the MTOC (8) that have the properties of aggresomes (52) . Similarly, in cells transiently transfected with an E1B-55K expression vector, E1B-55K and most of the cellular p53 are observed in large cytoplasmic inclusions with the properties of aggresomes in a large fraction of the cells (13, 18, 28, 52, 79) . But at 24 h posttransfection of an E1B-55K expression vector into p53 ϩ A549 cells, in addition to such cells, ϳ50% of the cells also contained p53 colocalized with E1B-55K in PML-nb (Fig. 3b and 6d and e). Since in virusinfected cells, where E1B-55K expression is more synchronous than in transfected cells, E1B-55K is first observed in nuclei associated with PML-nb (19, 48) , p53 first associates with E1B-55K in PML-nb (52) , and MRE11 follows a similar pathway of nuclear export (52), we interpret the association of E1B-55K and p53 in PML-nb to be an intermediate in p53 nuclear export. This interpretation is supported by the observation that E1B-55K mutant in its sumoylation site (22) (E1B-55K K104R) is greatly reduced in its interaction with PML-nb ( Fig. 6b  and c ) and for induction of p53 nuclear export ( Fig. 6d and e) .
A key observation for understanding the mechanism by which E1B-55K inhibits p53 function is that mutation of the consensus sumoylation site in the E1B-55K K104R mutant greatly interferes with E1B-55K inhibition of p53 transactivation function and consequently its ability to cooperate with small E1A in the transformation of primary rodent cells (22) . In stably transformed cells, the sumoylation site E1B-55K mutant accumulates in large cytoplasmic bodies (22) similar to those observed for WT E1B-55K in transformed cells (8, 83) and late during viral infection (52) . WT E1B-55K (45) and complexes including WT E1B-55K and E4orf6 (18) shuttle between the nucleus and cytoplasm. E1B-55K mutant in its sumoylation site (K104R) can also shuttle into nuclei when expressed in transiently transfected cells, as demonstrated by the retention of a large fraction of the mutant protein in nuclei of cells treated with leptomycin B to inhibit its nuclear export (Fig. 6c ) and when its NES (45) was additionally mutated (Fig.  6b) . Nonetheless, when the NES of the E1B-55K K104R sumoylation site is intact in cells not treated with leptomycin B, it is not retained in nuclei (22) . Earlier, this result was interpreted to indicate that E1B-55K sumoylation is required for its nuclear import, but the conclusion was qualified to indicate that sumoylation might be required for nuclear accumulation because of its requirement for targeting to specific sites in the nucleus (22) . We favor the latter interpretation, with sumoylation facilitating the association of nuclear E1B-55K with PML-nb, as observed for several PML-nb-associated proteins (34) . As a consequence of this reduced association with PMLnb, we suggest that E1B-55K nucleocytoplasmic shuttling (45) favors accumulation of E1B-55K in cytoplasmic aggresomes at steady state due to its dynein motor protein-dependent transport on microtubules to the MTOC (52). When E1B-55K K104R was retained in nuclei by inhibition of its nuclear export by treatment with leptomycin B during the time of its expression or by additional mutation of its NES (45) , it was observed in nuclei, where it formed large complexes with p53 that were only rarely associated with PML-nb ( Fig. 6b and c) . These results suggest that retention of WT E1B-55K in nuclei requires its association with PML-nb, which is dependent on its sumoylation. Since p53 nuclear export is severely inhibited in cells transfected with the E1B-55K K104R expression vector ( Fig. 6d and e) , it appears that E1B-55K association with PML-nb is required for efficient p53 nuclear export by E1B-55K.
We used the method of FRAP to measure the extent to which WT E1B-55K tethers p53 in PML-nb, lowering its free concentration available for binding to p53 response elements in cellular target genes. We observed an ϳ2-order-of-magnitude decrease in the nuclear mobility of p53-YFP when it was tethered in PML-nb compared to p53-YFP expressed under these conditions in the absence of E1B-55K (Fig. 3e) , where it strongly activates transcription from a cotransfected reporter gene (A.J.B. and M.A.P., unpublished results). When the otherwise low-abundance PML-IV isoform that binds p53 was overexpressed (6, 24), E1B-55K lowered the nuclear mobility of p53-YFP further, ϳ250-fold compared to p53-YFP alone (Fig. 3f) .
Proteins associated with PML-nb are often modified by sumoylation at a low level (1 to 10%) (34) . Muller and Dobner (57) reported that E1B-55K stimulates SUMO1 modification of p53 in vivo in transfected cells. We made similar observations for a p53-YFP fusion (Fig. 1d) . We also observed stimulation of p53 SUMO1 modification, and not SUMO2/3 modification, by E1B-55K in virus-infected cells at the normal protein concentrations achieved during viral infection (Fig. 1a  to c) . This suggests that adenovirus probably utilizes this function to optimize E1B-55K p53 inactivation during viral infection.
Since E1B-55K stimulates SUMO1 conjugation of p53 in vivo, we asked if E1B-55K might itself be a SUMO1 E3 for p53. We found that baculovirus-expressed E1B-55K stimulated p53 SUMO1 conjugation in a completely purified system using E. coli-expressed, purified rSUMO1 and human SUMOs E1 and E2 (Fig. 2a) . The observation that specific p53 sumoylation activity coeluted with rE1B-55K protein in gel filtration column fractions with no other proteins detectable by silver staining that coeluted with the peak of E3 SUMO1-p53 ligase activity ( Fig. 2c to f) virtually proves that the activity is intrinsic to the E1B-55K polypeptide and not a copurifying activity from insect cells or an insect cell SUMO1 E3 in a complex with E1B-55K, which would have eluted at a higher molecular weight.
Nuclear bodies such as PML-nb have been proposed to facilitate nuclear processes by concentrating proteins whose interaction is desirable and excluding proteins that might inhibit or be themselves damaged by processes that occur in the nuclear bodies (32) . Like E1B-55K, p53, and MRE11 in adenovirus-infected cells, other proteins have been found to enter and then exit PML-nb (5, 23) . The remarkable enigma, recapitulated here for p53, is that many transcriptional regulators are localized to PML-nb and inhibited even though only a small fraction of molecules are sumoylated at steady state. Only a small fraction of E1B-55K is sumoylated at steady state (22) , and only ϳ1.5% of p53 is sumoylated when most of the nuclear forms of these proteins are associated with PML-nb ( Fig. 1e and 3b) . Despite this low level of steady-state sumoylation, all of the p53-YFP in PML-nb is tethered, as shown by FRAP (Fig. 3e) .
Experiments using the chicken adenovirus CELO Gam1 protein, an inhibitor of SUMO E1, indicate that SUMO1 groups are removed rapidly after their addition (9) . It has been postulated that, once sumoylated, repressed transcription factors remain inhibited because they are bound by other inhibitory proteins after the SUMO group is removed (34) . E1B-55K induces exportin 1 (CRM1)-dependent export of p53 from nuclei (18, 45) (Fig. 6c) , raising the possibility that some component of the exportin 1-dependent nuclear export mechanism might be the inhibitory protein that binds p53 once it is marked for export by transient sumoylation. Certainly, the ensuing export to the cytoplasm inactivates p53 as a transcriptional activator by eliminating it from the nucleus. p53 sequestration in cytoplasmic inclusion bodies and aggresomes at the MTOC would also interfere with any direct influence of p53 on cytoplasmic processes, such as activation of mitochondrion-initiated apoptosis pathways and inhibition of autophagy (31) .
A molecular network such as that diagrammed in Fig. 7b may also contribute to the ability of a small fraction of E1B-55K and p53 sumoylation to contribute to the tethering of unsumoylated p53 in PML-nb. Since E1B-55K is a dimer (54) that binds to the random coil N termini of p53 tetramers (39, 40, 50) , it should have the capacity to form such a multiprotein network. This possibility is supported by our observation that purified E1B-55K and p53 formed high-molecular-weight complexes excluded from a Superose 6 gel filtration column (Ͼ4 MDa), whereas the proteins incubated individually under the same conditions did not (Fig. 7c) . While only a portion of the highly purified p53 and E1B-55K proteins formed complexes large enough to elute in the void volume of the Superose 6 column, much of the E1B-55K and p53 eluted in higher-molecular-weight fractions when the two proteins were incubated together than when they were incubated alone. Molecules that did not shift in molecular weight may not have been fully functional. Also, the protein concentrations reached in cell nuclei are far higher than those in these in vitro reaction mixtures, favoring complex formation. Once a large network of interacting proteins has formed, interactions between SUMO groups linked to a small fraction of the molecules in the network (Fig. 7b) and SIMs in abundant PML-nb proteins such as the various PML isoforms (5, 35, 42) would contribute to the tethering of all of the proteins in the network. This is similar to the model of the formation of PML-nb through interactions between SUMO groups covalently bound to the various PML isoforms and a SIM in the PMLs (69) , except that PML isoforms form dimers rather than large multiprotein networks and ϳ50% of the PML molecules are sumoylated (58) , in contrast to ϳ1.5% of the p53 and E1B-55K molecules. Consequently, formation of a multiprotein E1B-55K-p53 network is essential for tethering virtually all of the nuclear E1B-55K and p53 in PML-nb when such a small percentage of the molecules are sumoylated. In support of this model, a mutant form of p53 unable to form tetramers and therefore to generate a network such as that diagrammed in Fig. 7b was tethered to a greatly reduced extent in PML-nb compared to WT p53, as measured by FRAP (Fig. 7e) . However, this p53 mutation would not be expected to completely disrupt molecular networks formed by E1B-55K in vivo, since E1B-55K also binds to the MRN complex, which is a dimer (36) and so can also form a molecular network with E1B-55K that could incorporate p53 monomers. Also consistent with this network tethering model, we found that a 2-to 3-fold decrease in p53 sumoylation caused by mutation of the p53 SUMO modification consensus sequence (p53 mutant K386R, Fig. 1e ) resulted in a decrease in p53 tethering in PML-nb, as measured by FRAP (Fig. 3f) . A recent report indicated that a mutant p53 protein that forms a monomeric protein as opposed to the WT p53 tetramer is not bound by E1B-55K in vivo (56) . Our finding that the p53 L344P mutant, well established to be a monomer (16) , is bound by E1B-55K in PML-nb (Fig. 7d ) contradicts this conclusion. On the other hand, these authors also reported that the p53 mutant monomer they analyzed was not efficiently exported to cytoplasmic E1B-55K inclusion bodies (56) , a result we also observed for the p53 L344P monomer (Fig. 7d) . We also noted that E1B-55K formed a shell around PML-nb formed with the p53 L344P mutant protein, possibly reflecting a defect in the way E1B-55K complexes with monomeric p53 interact with other cellular components required for its nuclear export. These authors also characterized E1B-55K mutant proteins that failed to coimmunoprecipitate when expressed with two different epitope tags (56) . This is the expected result for E1B-55K mutant proteins that fail to dimerize like WT E1B-55K (54) . The fact that these mutant proteins were also defective in the ability to induce p53 nuclear export and association with E1B-55K cytoplasmic inclusion bodies (56) is consistent with the model in which an E1B-55K-p53 molecular network such as that diagrammed in Fig. 7b is necessary for interactions in PML-nb required for E1B-55K-induced p53 nuclear export.
Unlike the situation with E1B-55K, where mutation of the sumoylation consensus sequence eliminates E1B-55K sumoylation (22) , as observed for several other sumoylated proteins associated with PML-nb (34), mutation of the p53 sumoylation consensus sequence reduced p53 sumoylation only ϳ2-fold. This resulted in a modest decrease in inhibition of p53 transactivation function (Fig. 4a and b) , probably because of decreased tethering in PML-nb, as assayed by FRAP (Fig. 3f) . Still, the decrease in p53K386R-YFP nuclear mobility caused by E1B-55K-induced tethering in PML-nb was considerable compared to that of p53-YFP expressed in the absence of E1B-55K. This persistent tethering in PML-nb probably contributes to the E1B-55K repression of transcriptional activation by p53K386R. The residual sumoylation of p53K386R is not due to sumoylation at a single secondary site, since mutation of every other p53 lysine in combination with the K386R mutation failed to eliminate this low level of sumoylation (Fig.  5 ). This may be because p53 is stably bound by E1B-55K, which has SUMO1 E3 ligase activity (Fig. 2) . The ability of E1B-55K to function as a SUMO1-p53 E3 ligase also may contribute to the postulated network-tethering mechanism discussed earlier by adding additional SUMO1 groups to components of the network as soon as SUMO1 is removed by the high activity of desumoylating enzymes present in PML-nb (9, 34) .
